Previous 10 | Next 10 |
Evofem Biosciences ( NASDAQ: EVFM ) stock soared ~31% post market on Aug. 4 after Q2 net loss narrowed and the women health company reaffirmed its FY22 product sales outlook. Q2 net sales of birth control vaginal gel Phexxi grew +42% Q/Q to $6M. The com...
Evofem Biosciences press release ( NASDAQ: EVFM ): Q2 loss from operations improved 16% to $24.4M. Revenue of $6M (+215.8% Y/Y) misses by $0.05M . Evofem ( EVFM ) continues to expect net product sales in the range of $30M to $35M for its 2022 fiscal year, repre...
Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance PR Newswire -- 42% growth in Phexxi ® (lactic acid, citric acid and potassium bitartrate) net product sales quarter over quarter -- -- Red...
Evofem Biosciences Strengthens Board of Directors PR Newswire SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip , a Managing Partner at life sciences investment fund Adjuvant...
Phoenix, Arizona--(Newsfile Corp. - August 1, 2022) - The Stock Day Podcast welcomed Evofem Biosciences (NASDAQ: EVFM) ("the Company"), an innovator in women's sexual and reproductive health and the maker of hormone-free contraceptive Phexxi ® (lactic acid, citric acid and potassium bita...
Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women PR Newswire -- Top-line readout of data expected in October 2022 -- ...
Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals PR Newswire SAN DIEGO , July 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today comme...
Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022 PR Newswire -- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO , July 28, 2022 /PRNewswire/ -- Evofem Biosciences, In...
Evofem's House Rules Campaign Featuring Annie Murphy Receives Significant Industry Recognition PR Newswire Evocative direct-to-consumer (DTC) campaign has received 12 healthcare and communications industry awards to date and has recently been shortlisted for four mor...
Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling PR Newswire SAN DIEGO , July 25, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has developed a n...
News, Short Squeeze, Breakout and More Instantly...
Evofem Biosciences Inc. Company Name:
EVFM Stock Symbol:
NASDAQ Market:
Evofem Biosciences Inc. Website:
Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, along with its wholly owned subsidiary Adifem Inc., and Evofem Biosciences Inc. (OTCQB: EVFM) have amended and restated their previously announced merger agreement. Accor...
Evofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis Aditxt, Inc. (“Aditxt”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12...
2024-06-27 10:57:17 ET This company is striving to change the narratives around women's healthcare and offering solutions that reinforce and improve them. And shares are responding positively to a recent partnership announcement. Women's health innovator %EvofemBiosciences Inc. (OTC...